Skip to main content

Hypergastrinaemia

0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Trio Medicines
Trio MedicinesUK - London
3 programs
YF476PHASE_11 trial
YF476PHASE_11 trial
YF476PHASE_11 trial
Active Trials
NCT01699113Completed32Est. Jun 2007
NCT01601405Completed10Est. Nov 2001
NCT01601418Completed12Est. Jan 2002

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Trio MedicinesYF476
Trio MedicinesYF476
Trio MedicinesYF476

Clinical Trials (3)

Total enrollment: 54 patients across 3 trials

Effects of YF476 and Rabeprazole on Gastric Function

Start: Aug 2006Est. completion: Jun 200732 patients
Phase 1Completed

Effect of Repeated Doses of YF476 on Stomach Acidity

Start: Oct 2001Est. completion: Nov 200110 patients
Phase 1Completed

Effect of Single Doses of YF476 on Stomach Acidity

Start: Oct 2001Est. completion: Jan 200212 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.